In the past week, PACB stock has gone down by -8.27%, with a monthly decline of -10.29% and a quarterly plunge of -47.86%. The volatility ratio for the week is 9.28%, and the volatility levels for the last 30 days are 12.12% for Pacific Biosciences of California Inc The simple moving average for the past 20 days is -17.11% for PACB’s stock, with a -29.91% simple moving average for the past 200 days.
Is It Worth Investing in Pacific Biosciences of California Inc (NASDAQ: PACB) Right Now?
The 36-month beta value for PACB is at 2.01. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for PACB is 243.53M, and currently, shorts hold a 25.45% of that float. The average trading volume for PACB on March 17, 2025 was 11.29M shares.
PACB) stock’s latest price update
The stock price of Pacific Biosciences of California Inc (NASDAQ: PACB) has surged by 1.67 when compared to previous closing price of 1.20, but the company has seen a -8.27% decline in its stock price over the last five trading sessions. zacks.com reported 2025-03-14 that In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.22, denoting a +1.67% change from the preceding trading day.
Analysts’ Opinion of PACB
Jefferies, on the other hand, stated in their research note that they expect to see PACB reach a price target of $4. The rating they have provided for PACB stocks is “Buy” according to the report published on June 03rd, 2024.
PACB Trading at -23.86% from the 50-Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.15% of loss for the given period.
Volatility was left at 12.12%, however, over the last 30 days, the volatility rate increased by 9.28%, as shares sank -17.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.84% lower at present.
During the last 5 trading sessions, PACB fell by -8.27%, which changed the moving average for the period of 200-days by -34.76% in comparison to the 20-day moving average, which settled at $1.4718. In addition, Pacific Biosciences of California Inc saw -33.33% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PACB starting from HENRY CHRISTIAN O, who sale 12,497 shares at the price of $1.41 back on Mar 03 ’25. After this action, HENRY CHRISTIAN O now owns 2,225,357 shares of Pacific Biosciences of California Inc, valued at $17,583 using the latest closing price.
Van Oene Mark, the of Pacific Biosciences of California Inc, sale 6,486 shares at $1.41 during a trade that took place back on Mar 03 ’25, which means that Van Oene Mark is holding 1,497,695 shares at $9,126 based on the most recent closing price.
Stock Fundamentals for PACB
Current profitability levels for the company are sitting at:
- -2.66 for the present operating margin
- 0.2 for the gross margin
The net margin for Pacific Biosciences of California Inc stands at -2.0. The total capital return value is set at -0.33. Equity return is now at value -51.05, with -20.52 for asset returns.
Based on Pacific Biosciences of California Inc (PACB), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at 1.12. The interest coverage ratio of the stock is -51.8.
Currently, EBITDA for the company is -356.38 million with net debt to EBITDA at -0.67. When we switch over and look at the enterprise to sales, we see a ratio of 3.84. The receivables turnover for the company is 5.6for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.63.
Conclusion
In conclusion, Pacific Biosciences of California Inc (PACB) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
